DESCRIPTION
Amocrin CV 500mg/125mg Tablet is used to treat bacterial infections in the body that affect the skin, soft tissues, lungs, ears, urinary tract, and nasal sinuses. It should be mentioned that viral infections like the flu and the common cold are not treated by this medication.
Amocrin CV 500mg/125mg Tablet consists of two medicines: Amoxycillin and Clavulanic acid. Amoxycillin acts by destroying the outer protein layer, thereby killing the bacteria (bactericidal action). Clavulanic acid inhibits the enzyme beta-lactamase, which prevents bacteria from destroying the efficacy of amoxycillin. As a result, the action of Clavulanic acid allows Amoxycillin to work better and kill the bacteria. Amocrin CV 500mg/125mg Tablet does not work against infections caused by viruses, including colds and flu.
Uses
•Bacterial Infections: Amocrin CV 500mg/125mg Tablet helps treat bacterial illnesses, including pneumonia and bronchitis. The composition of Amocrin CV 500mg/125mg Tablet improves efficacy against resistant microorganisms.
•Sinusitis: Amocrin CV 500mg/125mg Tablet treats bacterial sinus infections by lowering inflammation and cleaning them.
•Urinary Tract Infections (UTIs): Amocrin CV 500mg/125mg Tablet treats urinary tract infections caused by susceptible bacteria and provides broad-spectrum protection
Directions for Use
Swallow it as a whole with water; do not crush, break or chew it.
Medicinal Benefits
Amocrin CV 500mg/125mg Tablet is a broad-spectrum antibiotic that covers a very wide range of bacterial infections. Amocrin CV 500mg/125mg Tablet has Clavulanic acid, which protects amoxycillin from getting destroyed by the bacterial enzyme, thus increasing its efficacy. Besides this, it helps overcome antibiotic resistance in bacteria that is caused by the enzyme beta-lactamase. This makes the drug effective in multiple infections like ear infections (acute otitis media), bronchitis, pneumonia, urinary tract infections, skin infections,
Side Effects
- Vomiting
- Diarrhea
- Indigestion
Reviews
There are no reviews yet.